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Abstract
It is known that hair growth disorders and hair loss can cause personal distress and affect 
well-being.  Whilst clinical conditions remain a target for medical research, current 
research on hair follicle biology and hair growth control mechanisms also provides 
opportunities for a range of non-medical and cosmetic interventions that have a 
modulating effect on the scalp and follicle function. Furthermore, an improvement of the 
hair fibre characteristics (cuticle structure, cortex size and integrity) could add to the 
overall positive visual effect of the hair array.  Since phytochemicals are a popular choice 
due to their traditional appeal, this review provides a critical evaluation of the available 
evidence of their activity for hair benefit, excluding data obtained from animal tests, and 
offers recommendations on improving study validity and the robustness of data collection 
in pre-clinical and clinical studies. 
Introduction
This consideration of phytochemicals for hair benefit requires an appreciation of hair 
follicle structural organisation and the context of the stages of the hair growth cycle.  This 
can be related to the most common pathologies of hair growth, as well as non-
pathological hair loss conditions that may still raise the perceived need for temporary 
non-pharmacological treatments.  Therefore, we begin with hair follicle and growth cycles 
and the most common hair loss conditions. We also include an overview of the commonly 
used pre- and clinical test methods and their contribution to the overall body of evidence 
regarding treatments for hair loss and we critically review both topical and oral 
applications in the context of the robustness and relevance of the reported test methods, 
data produced and interpretation of results. The review concludes with an assessment 
of the current scientific approaches to phytochemical product evaluation with 
recommendations for future developments. 
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Methods
Various search terms - hair loss, hair growth, human follicle, phytochemicals, plant 
actives - were used to search the following databases: PubMed, Science Direct, Scopus 
and Google Scholar. Further manual searches were conducted to access relevant 
reference sources in the identified articles.  Original articles, review articles and opinion 
pieces published from 1990 to the current date were included. 
The following final article selection criteria were applied: 
1. Original research including human cell cultures, hair follicles and human volunteer 
testing was reviewed. Whilst the research value of data, past and current, based on 
murine cell, follicle and in vivo models is undisputed, differences between human 
and animal models, as well as the drive to reduce animal testing, have raised the 
demand for robust human-based data;
2. Phytochemicals including individual or optimised chemical mixtures, as well as plant-
derived extracts such as oils and extract mixtures were searched. This criterion 
reflects the non-medicinal approaches to symptom relief of a range of dermatological 
and hair related conditions, whereby complementary rather than purely 
pharmacological activity is sought;
3. Preparations applied topically or for oral use were included, but not those that were 
applied in combination with medicinal or light therapies. This criterion maintains the 
focus on complimentary treatments;
4. Review articles and opinion pieces, which were focused on test methods or on 
phytochemicals/naturally derived mixtures, were included. 
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The hair follicle 
The hair follicle (HF) is a mini organ of the skin, extending from the epidermis into the 
lower dermis, tubular in shape and widening into a bulb at its lower end. Its anatomy, 
structure physiological role and regenerative nature is well described [1-3], although 
many aspects of its biology remain unclear [4]. Enclosed by the follicle bulb sits the 
dermal papilla (DP), consisting of spindle-shaped fibroblast cells referred to dermal 
papilla cells (DPC); connective tissue components and a capillary network.  The lower 
DP is surrounded by the hair bulb containing hair matrix keratinocytes (HMK). During the 
active hair growth periods, HMK proliferate and cells are ‘pushed’ upwards, whilst 
undergoing lineage specific differentiation and keratinisation. This results in the 
formation of the three structural compartments of the hair fibre, medulla, cortex and 
cuticle and the follicle inner root sheath (IRS) that plays a role in the shaping of the hair 
fibre [5], and the companion layer [6]. The follicle is encased by the outer root sheath 
(ORS), which contains stem cells that play an active role in the initiation of the hair growth 
cycles [7, 8]. Melanocytes are located in the bulb matrix overlying the DP, where they 
are actively producing melanin in hair growth, as well as being present in the ORS where 
they are inactive but contribute to the re-pigmentation of the follicle during a new hair 
growth cycle. During the active hair growth periods, the melanocytes produce 
melanosomes which are distributed within the proteins of the cortical cells to afford the 
variety of hair colour [8]. A healthy human scalp holds between 100 000 - 120 000 HFs.
At any given time, between 80 and 90% of the HFs on a healthy scalp are in the stage 
of active hair fibre growth. This makes a full head of hair, which is known to present an 
important factor in individual’s well-being.  Reduced quality of life and other measures of 
well-being have been reported in patients with hair loss conditions [9-11].
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Hence, in the last two decades, the endogenous and exogenous factors regulating the 
HF activity, as well as the pathological and age-related changes to hair follicle, have 
gained further attention from both medical and non-medical researchers.   
Hair growth cycle
It is widely accepted that the HF undergoes four phases, resulting in the production of a 
hair fibre (anagen), regression (catagen), resting (telogen) and fibre shedding (exogen). 
The anagen or the fibre growth stage is characterised by intense metabolic activity within 
the DP and the rapid proliferation (mitosis) of HMKs within the bulb. The mitotic rate of 
HMKs is amongst the highest in the human body [1]. Simultaneously, the bulb 
melanocytes produce melanin, which is transferred to the cortical cells via melanocyte 
dendrites. Follicles producing terminal scalp fibres will remain in anagen for 2-6 years, 
with hair growth maintained at around 1cm per month. The commencement of the 
regression stage, catagen, is marked by the repression of proliferation and an apoptosis-
driven HF organ involution, which commences with a switching off of melanogenesis [8, 
12]. The remnant HMKs differentiate to form an unpigmented ‘club’ at the proximal end 
of the fibre, and the club hair is shed during the telogen or early subsequent anagen. 
The termination of melanogenesis during the transient anagen-to-catagen phase is 
accredited to the reduced activity of hair bulb melanocytes and a decrease in the 
expression and activity of the enzyme tyrosinase (TYR) [8]. At the same time, the DP is 
protected from apoptosis by the upregulation of immune privilege (IP) [13, 14].
During the telogen or resting phase, the HF remains in a quiescent stage for 
approximately 8-12 weeks, until the commencement of the subsequent anagen, 
sometimes referred to as neogen stage [15]. During early anagen, progenitor cells 
located within the ‘bulge’ are activated, and the hair bulb is regenerated. The bulge is an 
anatomical label mostly used in murine hair growth. In human hair follicles the epithelium 
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around and immediately below the telogen club hair defines one region of stem cells with 
the ORS containing further populations [16-18]. The DP is critical in HF regeneration with 
DP cells having hair regeneration properties [19, 20].  It is also believed that the shape 
and size of the DP defines the size of the hair fibre [21-24]. The anagen fibre is extruded 
through the follicle ostium and the remnant club hair from the previous cycle is shed in a 
process known as exogen at an indeterminate stage of the hair cycle [25].
More recently, a suggested adaptation to this model has been published, proposing that 
the HF organ exhibits a bi-stable equilibrium [15]. According to this theory, the follicles 
shift between steady states of growth (anagen) and rest (telogen), with an intermediate 
transitory phase of either degradation (catagen) or neo-morphogenesis (neogen). The 
process is stochastic but autonomous for each follicle, with the roles of different HF 
compartments and signalling being still insufficiently understood. This type of critical 
thinking helps to determine whether the strategy for treatment is one of influencing hair 
growth at the transition points or maintaining the steady state between cyclic transitions.
Hair loss conditions 
It is proposed that ‘hair loss’ or ‘thinning’ is a multi-factorial perception of hair density, 
fibre diameter, hair colour and degree of curl, which together contribute to the overall 
perception of scalp coverage [26]. Hair loss includes androgen mediated alopecia (AGA) 
as well as the diffuse hair thinning on the crown more typical of female pattern hair loss. 
AGA is the most commonly investigated hair loss condition and also presents the 
broadest range of interventions due to the variations of its manifestations. AGA is 
mediated by androgen action in susceptible hair follicles, like those in the temple and 
vertex in male scalp and those of the temple in older females [27-29]. The conversion of 
testosterone to the more active metabolite dihydrotestosterone (DHT) is catalysed by 
cytoplasmic 5-reductase enzymes within the DP cells [30]. Testosterone and DHT form 
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receptor-ligand complexes with the androgen-receptor (AR), but DHT exhibits a greater 
degree of affinity with the AR than testosterone. It is therefore understood that inhibition 
of 5-reductase will significantly ameliorate AGA and finasteride and dutasteride have 
emerged as hair growth drugs which inhibit 5 alpha reductase [31] [32, 33]. 
Hair loss that is not immediately attributable to action of hormones includes auto-immune 
disorders such as Alopecia Areata (AA) and inflammatory scalp disorders such as 
Cicatricial Alopecia (CA) which results in scarring and permanent hair loss. Periods of 
excess hair shedding, which typically presents as a diffuse and transient disturbance of 
the hair cycle, are referred to as Telogen Effluvium (TE). Hair thinning associated with 
ageing (Senescent Alopecia) is of concern to older people and hair loss due to excessive 
mechanical stress on the hair follicle (Traction Alopecia) is common in people with very 
curly hair who adopt styles involving tight braiding. Poor scalp health such as in dandruff 
and seborrheic dermatitis can also be linked with temporary shedding. All forms of hair 
loss are targets for complimentary treatments, as discussed below. A summary of these 
conditions and their common treatments is presented in Table 1. 
Table I: A summary of the different types of alopecia, their aetiology and manifestations 
as well as the typical proscribed treatment.  
Alopecia 
progenies
Aetiology Histopathology Treatment
Androgenic 
Alopecia 
(AGA)
Androgen 
dependant 
(testosterone/DHT) 
follicle 
miniaturisation
Female – diffuse hair 
loss (Ludwig), often 
related to 
hyperandrogenism 
Male – often manifests 
as a receding hair-line 
Topical Minoxidil 
(2%)  
Topical Minoxidil 
(5%)
Oral Finasteride/ 
Dutasteride 
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and hair loss in the 
vertex region (Hamilton-
Norwood)
Hair transplantation
Alopecia 
Areata (AA)
Regions of ‘patchy’ hair-
loss, which 
predominantly manifest 
in the scalp.
Topical Minoxidil 
(5%) Topical or oral 
corticosteroids
Alopecia 
Totalis (AT)
Complete absence of 
terminal scalp fibres
Wig/ Hair 
transplantation
Alopecia 
Universalis 
(AU)
T-cell dependant 
auto-immune 
disorder
Complete absence of 
scalp and bodily fibres
Wig
Cicatricial 
Alopecia 
(CA)
Inflammation of the 
upper part of the HF 
leading to 
irreversible damage 
of the hair bulge 
and the loss of stem 
cells  
Permanent loss of hair in 
the affected patches, 
visible scarring may 
occur
Topical or oral 
antibiotics, 
corticosteroids; 
Scalp reduction 
surgery
Hair transplantation 
Senescent 
Alopecia 
(SA)
Stochastic ‘ageing’ 
of the follicle caused 
by UV, reactive 
oxygen species and 
other endogenous 
and exogenous 
stressors 
Gradual decrease in 
fibre-diameter and the 
number of anagen-
follicles, resulting in a 
diffuse hair-loss across 
the entirety of the scalp 
(non-androgenic)
Topical Minoxidil   
Cosmetic 
intervention
Topical antioxidants 
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Traction 
Alopecia 
(TA)
Persistent or 
significant strain to 
the follicle, caused 
by particular 
grooming practices 
(Inc. braiding, tight 
pony-tails)
Scarring of follicles and 
hair-loss at the 
frontotemporal margin of 
the scalp 
Acute: anti-
inflammatory 
agents
Chronic: Hair 
transplantation
Telogen 
Effluvium 
(TE)
Numerous ‘triggers’ 
including 
physiological and 
metabolic stress 
Non-scarring diffuse hair-
loss, characterised by the 
simultaneous shedding of 
telogen fibres
Cosmetic 
interventions: 
topical antioxidants 
and 5-α reductase 
inhibitors 
Measurement approaches used to determine treatment benefits for hair loss
The study of the potential benefits of botanicals for common and disease-related hair 
loss employs many human pre-clinical models and clinical evaluation methods. 
Understanding the benefits and limitations of such assays is important in the 
interpretation of the data on treatments. 
Hair loss involves alteration to the hair cycle or change to the size of the follicle that 
affects visible hair, so Phototrichogram (PTG) methods are one of the most useful 
methods for clinical evaluation. They givie an accurate measure of the unit area hair 
density and the terminal- to-vellus hair ratio using a hair diameter cut off of 40µm.  PTGs 
can give an insight to the underlying hair follicle biology, but can underestimate follicle 
density by not including telogen follicles that have shed the club hair, a sub-phase termed 
Kenogen, [34]. PTGs are usually used to follow a scalp site at intervals of one month, 
Page 8 of 42
International Journal of Cosmetic Science
International Journal of Cosmetic Science
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
however, they are rarely used to follow individual follicle activity. Therefore, PTGs 
measure average changes of hairs growing in the site. 
The ex vivo human hair follicle (HF) model employs intact truncated anagen hair follicles 
isolated from scalp skin and then placed in organ culture [35]. The development and use 
of a fully defined medium for ex vivo hair growth is an advantage when testing added 
hair actives. However, while hair fibre formation is observed over a period of a few days, 
the model reflects maintenance of anagen status, comparing treatments with control. 
Although treatments can improve maintenance of HF, many authors refer to this as an 
increase in ‘hair growth’. Importantly, as the HFs are usually cultured for periods of only 
5-16 days, the range of intrinsic pre-programmed factors i.e. gender, scalp location and 
general health of the donor might have a stronger effect on the growth rate than any 
treatment [36, 37]. 
Dermal papilla cells (DPC) have been used in vitro for evaluating hair growth benefits of 
many phytochemicals, recently comprehensively reviewed by Madaan et al. [38]. 
Commonly, anything that encourages or increases DPC expression of Insulin Growth 
Factor-1 (IGF-1) and Vascular Endothelial Growth Factor (VEGF) are interpreted as 
anagen-prolonging, whilst any induction of Transforming Growth Factor  (TGF-) 
expression is considered as catagen-inducing. The expression of proteins Bcl-2 and Bax 
and their ratio are also used as markers for apoptosis in DPCs [38]. However, caution 
must be used when interpreting data as DPC from the more typically used occipital site 
in men and parietal sites in women do not have androgen receptors [24]; this restricts 
their use for studies of effects of androgens. Furthermore, DPC very rapidly lose their 
hair induction phenotype in in vitro culture [19] and it is not clear that proliferation plays 
a role in DPC in normal hair growth in vivo, hence studies that use DPC proliferation to 
predict hair growth may not translate into the in vivo situation. The introduction of three-
dimensional sphere-like DPC models with or without added ORS cells, has made a major 
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advance and studies using these models are likely to be more useful to predict in vivo 
benefits [19, 39, 40]. Finally, for topical products to be effective via action in the DP, the 
actives need to be able to penetrate into the scalp and to reach the DPC directly or via 
the local circulation. Few studies explore this in detail; however, well-controlled clinical 
studies that show vehicle only effects vs measurable clinical efficacy can infer some 
active ingredient penetration necessary to generate the benefit.
Phytochemicals for hair loss treatment
Phytochemicals are often the sought-after choice of hair loss treatment; due to the 
appeal such actives hold with the consumer/clinical patient and their non-drug status.  
Furthermore, many phytochemicals are recognised for their role in traditional plant-
based treatments of skin and hair conditions, and a body of scientific literature related to 
their medicinal applications may already exist. Those materials that have HF and or DPC 
biological activity and/or in vivo clinical data are reviewed below. A full list of the reviewed 
studies, meeting the selection criteria, including summaries of the tests applied, key end 
points and conclusions on activity against targets, has been presented in Table II. 
Caffeine
Caffeine is a purine alkaloid, derived from several sources including coffee beans, 
tealeaves and cocoa and kola nuts. Its most well known mechanism of action is a 
competitive inhibition of the enzyme phosphodiesterase (PDE), which breaks down 
cyclic adenosine monophosphate (cAMP). By impairing the degradation of cAMP, thus 
leading to its intracellular replenishment, caffeine has the effect of activating protein 
kinase A and inhibiting leukotriene synthesis, which in turn reduces micro-inflammation 
and stimulates cellular proliferation [41, 42]. These mechanisms are of relevance to hair 
growth modulation. In addition, caffeine’s anti-oxidant activity, via scavenging hydroxyl 
and alkoxyl radicals and its ability to inhibit 5α-reductase, are all of relevance to 
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stimulating scalp hair growth [43]. Consequently, a wider range of caffeine studies is 
available, documenting its HF permeation and follicle activity, compared with any other 
natural/nature-identical compound. 
The dose-dependent effect of caffeine combined with testosterone (5 g/ml) on vertex µ
HFs affected by AGA (male donors) was examined by Fischer [42]. After 120 h, the 
testosterone metabolised by the HFs inhibited HF elongation in comparison with the 
control growth media, whilst the addition of caffeine at 0.001% and 0.005% counteracted 
this effect, strongly suggesting inhibition of 5α-reductase. Immunohistochemical staining 
of the HF within the same study showed increased HMK and ORS cell proliferation in 
the presence of caffeine. In a later study by the same authors, it was also demonstrated 
that HF responses to caffeine treatment are gender dependant and in vitro tests on 
ORSCs, demonstrated caffeine’s modulating capacity on the growth factors IGF-1, 
keratinocyte growth factor (KGF) and TGF-β2 that were comparable with minoxidil [44].  
A large number of in vitro caffeine permeation studies based on human or porcine tissue 
have been published and the HF ‘shunt route’ presents an effective penetration route for 
caffeine, irrespective of the target [45].  In vivo investigations involving the HF ‘shunt’ 
route of delivery demonstrated caffeine availability in the blood serum and within the HF 
following a single topical application for 24-48 hours [45-48]. A multi-centre in vivo study 
(n=210) [49] compared the efficacies of a leave-on 0.2% caffeine solution and a 5% 
minoxidil treatment on the scalp of male AGA patients (Hamilton-Norwood scale: III 
Vertex to V). A designated dose of treatment product was applied twice daily for 6 months 
and the primary end-point was the anagen/telogen ratio measured via PTG. The two 
groups presented similar (not statistically significant) improvements of 11.68% and 
10.59% in the ratio (baseline vs. 6 months). The authors concluded that a 0.2% caffeine 
solution was not inferior to 5% minoxidil.  However, the study did not include a placebo 
group, thus it is difficult to ascertain to what degree the interventions might have been 
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affected by seasonal and other exogenous factors.  While these studies are informative, 
each potential product type (solution/tonic/shampoo) requires specific investigation, 
reflecting more precisely the context of the application technique and caffeine 
concentration levels present. 
Recently, the caffeine’s potential to modulate the HF responses to UV radiation was 
demonstrated in a study applying topically 0.1% caffeine to skin specimens including 
terminal HF. The authors demonstrated that a combination of high dose UV (A+B) 
radiation induced HMK apoptosis, as well as the down-regulation of IGF-1 and the up-
regulation of TGF-2 in the proximal (nearest to the scalp) end of the HF, whilst the 
application of caffeine for 3 days before and 3 days after radiation alleviated these effects 
[50]. The authors suggested that the caffeine’s anti-oxidant and DPE-inhibition activities 
confer UV-protection properties.
Caffeine is also presented in various cosmetic hair care products, such as shampoos 
and conditioners. While not intended for hair loss treatment, product benefits relevant to 
consumers concerned with hair thinning have been evidenced [51].  As a small and 
hydrophilic molecule, caffeine could contribute to water binding in the hair fibre, thus 
improving its plasticity. 
In conclusion, caffeine is the most studied phytochemical for hair loss and the various 
caffeine studies reported offer reasonable evidence that, when dosed adequately, 
caffeine will become present in the HF at levels that support its biological activities and 
over a sufficient period of time, could result in ameliorated hair loss in some patients. 
Furthermore, caffeine-containing products offer potential for multi-benefit solutions for 
consumers suffering hair loss. However, for cosmetic applications, each new formulation 
will require clinical and/or consumer testing with appropriate end-points to avoid 
generalising about the benefits of caffeine for the hair loss patient or consumer.
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Polyphenols 
Polyphenols are a group of naturally occurring bioactive molecules used in a wide range 
of therapeutic products due to their health promoting effects. Polyphenols protect plants 
from different biotic and abiotic stresses (UV radiation and ROS-induced lipid 
peroxidation) due to their ability to scavenge free radicals.  They present an interesting 
opportunity within the hair-growth sector, as they are potent anti-oxidants and anti-
inflammatory agents [52, 53] [54]. Epigallocatechin-3-gallate (EGCG) has been identified 
as an integral polyphenolic catechin (monomeric flavan-3-ol) of green tea (Camellia 
sinensis L.) with well-documented anti-oxidant properties.  
As oxidative stress and micro-inflammation have been demonstrated to contribute to the 
ageing of HFs and the diminishing melanocyte stem cell production [55-59], therefore 
EGCG is a suitable phytochemical treatment for some hair loss conditions.  
An extensive exploratory study of the effect of EGCG on hair growth modulation as 
conducted ex vivo and in vitro using HFs in active anagen [60]. EGCG increased HF 
elongation by up to 123% in comparison with the control growth media. DPCs from HFs 
from patients treated with EGCG also presented a dose-dependent response of 
increased expression of survival mediating proteins P-Ekt and Bcl-2, and the apoptosis 
suppression protein Bax, thus corroborating the ex vivo data [60].
In another more recent study, EGCG elicited a dose-dependent improvement in the 
viability of DHT-treated DPCs [61]. Reduction in cell-senescence due to DHT-mediated 
elevation of ROS was detected and using a microarray analysis, the investigators 
identified a range of target genes that were up- or down-regulated in the DHT-treated 
DPCs in the presence of EGCG. These were associated with the cellular pathways of 
anti-oxidation, apoptosis, proliferation and cell cycle regulation, which are likely to be 
important in addressing hair loss.   
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Recently, the potential benefits of EGCG for treatment of the autoimmune hair loss 
condition, AA were reported, where the EGCG appeared to preserve immune privilege 
in an ex vivo assay, by inhibiting gamma interferon (IFN-γ) pathways, [62]. Blood 
samples from female patients with active hair loss and diagnosed AA were compared 
with age-matched healthy controls. Inflammatory T cells and intracellular cytokines 
(CD4, IFN-γ, IL-17) in AA patients’ samples were increased in comparison to controls, 
thus confirming their role in the pathogenesis. Both patient PBLs and HKC (HaCat) were 
incubated with IFN-γ, and treated with 40µM EGCG, which specifically inhibited JAK2 
expression, thus blocking the IFN-γ pathway known to reduce the immune privilege of 
the HF [62].
It has been demonstrated that EGCG could induce proliferation of aged human 
epidermal keratinocytes (in vivo) in comparison with vehicle (ethanol/propylene glycol) 
and that ECGC has an anti-apoptotic effect on human epidermal keratinocytes subjected 
to UV-induced oxidative damage, thus suggesting potential scalp care efficacy [63]. Such 
results on the epidermis is complementary to the HF-focused studies and would reflect 
the conditions of clinical studies that include formulations designed for improved product 
aesthetics, scalp health and user compliance.  However, despite all this promising pre-
clinical data, actual clinical data on the effects of EGCG on AGA and other non-AGA hair 
loss conditions is still lacking.
Another polyphenolic phytochemical, procyanidin B-2 isolated from apple juice (Malus 
pumila), was reported to ameliorate hair loss in Japanese men, based on its anti-
oxidative and anti-inflammatory properties [64, 65]. The effect of 1% active vs placebo 
was assessed in vivo in a 6 month study using PTG and two primary end-points were 
reported: increases in the total hair density and the A/T ratio (hair diameter > 40µm). 
These studies were conducted only on Japanese males. It is not clear whether 1% 
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procyanidin products will be effective in FPHL, which highlights the need to adapt the 
study design to the different presentations of hair loss in different races and genders. 
In studies examining the potential effects of polyphenols from other plant sources, Shin 
et al tested purified polyphenols from Ecklonia cava (Ec), sourced from marine brown 
alga, with enriched eckol content and showed they elicited improved DPC proliferation 
and increased expression of growth factors (IGF-1 and VEGF) whilst reducing the 
oxidative stress induced by H2O2 in vitro [66]. It was concluded that DPC proliferation 
was dose-dependent and the compound nature of the purified polyphenols + eckol was 
beneficial in comparison with that of the individual anti-oxidant components. Enhanced 
Trifollium Pratense extract also elicited reduced inflammatory response in DPCs and 
improved A/T ratio in a pilot clinical study. In another study, a proprietary herbal blend 
(including camomile and nettle) reduced apoptosis and increased cell viability of DPC 
from healthy humans [67]. 
Other actives of interest with clinical data are red clover extract [68]; raspberry ketone 
[69]; capsaicin from red chilli [70]; rosemary oil [71]; onion juice [72]; saw palmetto [73]; 
nettle/camomile and an undisclosed proprietary herbal blend [74].  Korean red ginseng 
extract (RGE) contains a range of bioactive constituents. A group of saponins, also 
referred to as gingsenosides, have been tested for their potential to promote hair growth 
and overall capacity to prevent oxidative damage in cells; recently reviewed by Choi 
2018 [75].  
In in vitro studies, RGE and isolated ginsenoside-Rb1 (G-Rb1) and ginsenoside-Rg3 (G-
Rg3) were tested on HMKs and DPCs and isolated HFs.  The extract and ginsenoside-
Rb1 induced proliferation of HMKs but not of DPCs. In another test, DPCs were pre-
treated with the actives, then incubated in DHT for 12 h. Predictably, DHT was found to 
upregulate the androgen receptor (in comparison with control), whereby the active pre-
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treatments mitigated this effect [76]. Panex ginseng ginsenosides were also able to 
antagonise the androgen driven anagen-to-catagen transition, suggesting it may prolong 
anagen [77]. In a further, study ginsenoside F1 was found to reduce apoptosis in UV-B 
radiated human keratinocytes [78]. A range of in vitro tests elicited a dose dependent 
increase in cell viability, reduced cell DNA fragmentation and counteraction of the UV-B 
induced down regulation of Bcl-2. The anti-apoptotic activity of this compound is akin to 
that of polyphenols and offers opportunities for scalp care, which could complement the 
HF-directed intervention.  
Oral phytotreatments
The demand for non-medicinal treatments of mild and age-related conditions of hair loss 
lends itself to more holistic approaches, including ingestible treatments. A small number 
of in vivo oral supplement-based tr atments of hair loss have been reported in the 
literature. However, in addition to the small test groups, lifestyle and other confounding 
variables are typically not fully reported, hence the results are to be treated with caution. 
Oral capsaicin and isoflavone improved total hair count in a placebo, double blind study 
including AA, AT and AGA patients. The active group also showed increased IGF-1 
levels in their blood serum in comparison to baseline values [79]. Saw palmetto was 
tested vs. finasteride oral treatment of AGA patients, with hair growth in the vertex area 
being comparable to the drug [80]. In another study, saw palmetto and β-sitosterol 
improved hair density, based on blind expert score [81]. Pumpkin seed oil, containing 
phytosterols [82] was tested in a double-blind, placebo-controlled study of male AGA 
patients.  The active group demonstrated statistically significant increase in hair count 
(density) in comparison with placebo.    
More complex blends, such as marine proteins and plant-derived actives, elicited higher 
total hair count and density in males with AGA (Norwood scale II and III) [83], as well as 
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total hair count and the hair diameter of fine hair in healthy females with self-perceived 
thinning hair [84-87]. These studies lasted 6 months and included placebo groups. The 
authors concluded that food supplements could provide alternative treatments to hair 
loss in males with less severe AGA, as well as females who perceive hair loss akin to 
TE due to life factors.  
A common challenge with the interpretation of all in vivo data in the context of hair growth 
cycles is the lack of detail on the timing of tests, as seasonality in hair loss is well 
documented [88] and could interfere with the results, despite the use of placebo. 
Furthermore, the grading reported in some of the studies is reliant on one clinical 
assessor and is not based on any validated scales. 
Discussion  
In summary, whilst the range of phytochemicals proposed for treating hair loss is 
promising and growing, the number of clinical studies published so far is low and a 
common set of criteria for evaluating effective interventions with such preparations is 
generally lacking.  
It is notable, however, that all investigated phytochemicals have well-documented 
pharmacological activities and pathways, which hair researchers have also identified as 
potential regulators of hair growth using cell and organotypic assays. Several of the 
above studies have explored the mechanisms and biomarkers in hair follicles or derived 
cells, based on gene expression and inter-cellular signalling, with the results 
corroborating the broader data, mostly acquired via animal testing.   Comprehensive 
reviews of in vitro HF keratinocyte or DP cell data (human and murine) [38, 89], converge 
on the following key mechanisms: cellular viability and proliferation in the DP, apoptosis 
modulation, 5α-reductase inhibition, inflammation reduction, related to the most 
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commonly identified outcomes.  Caffeine, phenolic compounds and phytosterols are 
therefore the preferred choices for androgenic hair loss, as evidenced by the available 
literature. Furthermore, studies using cultured HF demonstrate dose-responses to the 
above treatments. To improve the relevance of in vitro models, it is suggested that DP 
3D spheroids are adopted, due to their hair inductive ability [19, 90, 91].
Another challenge to current in vitro and ex vivo data is its focus on the catagen-inducing 
signalling in anagen HFs. However, according to Bernard [4], in vivo data suggests that 
the responding follicles are not all in anagen, but some are in the resting stage, hence 
further understanding of the HF responses to these phytochemicals is necessary, 
specifically on the modulation of telogen to anagen transition.  
Another feature of the published ex vivo tests is their application of a single 
phytochemical or simple mixtures. However, the complexity of the HF organ and its self-
regulatory processes, including the importance of blood supply, neuroendocrine 
environment and the stages of the hair cycle, all suggest that a mixture of compounds, 
targeting more than one process, is likely to be more ffective [89].   Further evidence of 
the positive effects of some actives on HKC proliferation and/or antioxidant efficacy, 
which expands the range of strategies to conferring optimal conditions for healthy hair 
growth.  
Some phytochemicals (capsaicin, raspberry ketone, onion juice) were identified as 
stimulators of the perifollicular nerves, inducing immunological reaction and antigenic 
competition, thus offering potential alternative AA treatments. However, these 
approaches require more robust clinical evidence of their efficacy. 
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Finally, when critically reviewing the reports of clinical studies with phytochemicals 
(topically and orally applied), we conclude that there is an over-reliance on clinician’s 
scales and self-reported patient assessment. No histological data is presented, but the 
investigators infer biological activity based on known properties of the plant extract being 
tested.
Despite the sparse published peer reviewed data, in a patent review in 2015 of hair and 
scalp cosmetic treatments, Pawar [92] revealed that natural extracts were included in 
61% of patents’ treatments aimed at the single benefit of hair/loss prevention or alopecia 
treatment. Some of the patented actives were: (I) extracts: Moringa oleifera, Bamboo 
sap, Torreya nucifer seed, Mori radix, Scutelleriae radix, (II) phytochemicals such as 
apeginin and glabranin, with commonly listed activities such as up-regulation of DPC 
proliferation, inhibition of 5α-reductase, scalp blood vessel dilation, oxidative stress 
reduction. This data suggests that phytochemicals will remain an important source of 
therapeutic and alternative treatments for hair loss.  Hence, this critical review concludes 
with a set of recommendations for improved study validity, which could be of help to 
researchers. 
In summary, a combination of in vitro and/or ex vivo data with a well-designed clinical 
trial is recommended.  Based on in vitro studies to date, it is also desirable that gender 
specific studies are conducted when androgen-related hair loss is targeted.  
Ex vivo tests combined with clinical trials would be more helpful in ascertaining the 
mechanisms of hair cycle modulation by phytochemicals and the magnitude of effects 
recorded. For in vivo clinical studies, placebo control and recognition of the 
season/month of starting and concluding the study are recommended due to the 
interference with seasonal moulting [88]. Confounding factors such as nutrition when 
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topical products are tested, and the use of specific hair care products when nutritional 
supplements are tested, should be better accounted for.  For these studies, PTG offers 
a better range of end points than clinician’s scales, provided the trial is sufficiently long 
(at least 4-6 months). Conditions such as AA & CA are not candidates for such 
treatments as they require systematic monitoring of patients undergoing drug therapy, 
however, phytochemicals as adjuvant to drug therapy is likely to be of benefit to these 
patients. Finally, whilst HF studies shed light on the follicle’s responses to actives, it is 
uncommon to study scalp epidermis and dermis of sufferers of hair loss. The scalp skin 
is exposed to a range of exogenous sources of oxidative stress, sensitizers and irritants 
- solar radiation, pollution, water and grooming products – thus loss of structural integrity 
of the scalp skin barrier could be contributing to the regulation of the hair growth cycle, 
with short periods of excess shedding observed with dandruff [93].  Non-invasive studies 
such as trans epidermal water loss (TEWL) for scalp skin barrier integrity, redness and 
skin lipid peroxidation, as a proxy for levels of inflammation, as well as biopsy data of 
general scalp skin/hair morphology would reveal useful complementary information to 
the PTG-generated data. 
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Table II. A list of all reviewed phytochemical studies, including summaries of tests and assays, endpoint and results. 
Phytochemical Type of tests/substrate Endpoints & Result Mechanism of 
action
Reference
Topical treatments
Ex vivo HF organs (males with AGA 
Norwood-Hamilton stage III vertex 
and IV) + testosterone + caffeine in 
different concentrations (120h)
Ki-67 immunostaining  
Hair shaft elongation after incubation 
in testosterone and caffeine: 
recovery in combined media equal to 
normal growth media
HF growth rate between 24 to 192h 
treatment with caffeine = dose 
dependent 
Ki-67 HMK cells and ORS cells = 
increase  
Stimulation of 
HFK proliferation 
and 5α-reductase 
inhibition
Increased cell 
proliferation
[1]Caffeine 
In vitro/ex vivo 
/in vivo studies
Ex vivo HF organ serum-free culture 
(healthy females facelift) + 
testosterone (120h) or + 
testosterone + caffeine 0.0005% 
(120h) vs. normal growth media 
(120h)
Hematoxylin-eosin staining
Ki67 immunostaining and TUNEL 
immunostaining  
  
Hair shaft elongation: increase 
HF cycle score: increase 
Ki67 HMK cells: increase  
5α-reductase 
inhibition
Increased cell 
proliferation and 
reduced 
apoptosis
[2]
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Ex vivo HF organ serum-free culture 
(males with AGA Norwood-Hamilton 
stage III vertex and IV) + 
testosterone (120h) or + 
testosterone + caffeine 0.0005% or 
0.001% (120h) vs normal growth 
media (120h)
Ki67 immunostaining and TUNEL 
immunostaining
Hair shaft elongation 0.001% 
caffeine +/- testosterone after 120h = 
increase
HF cycle score = increase
Ki67 positivity (HMK) = increase  
 
5α-reductase 
inhibition and 
reduced oxidative 
stress 
Increased cell 
proliferation and 
reduced 
apoptosis
In vitro ORS cells (healthy males, 
eyebrow hair) 
Treated with caffeine at variable 
concentrations, minoxidil and 
tretinoin 
Ki67 immunostaining 
TSA immunofluorescence staining 
ORS cell proliferation = increase
Modulating TGF-β2 (catagen 
inducer) gene expression and 
protein secretion = decrease
Modulating IGF-1 and KGF (anagen 
prolonging) gene expression and 
protein secretion = increase 
Stimulation of 
ORS cell 
proliferation
In vitro ORS cells (healthy males, 
eyebrow hair) 
Treated with TGF-2 or anandamide 
+ caffeine 0.001% or IGF-1 or KGF, 
CyQUANT
ELISA and  Q-PCR analysis
ORS proliferation = increase
IGF-1 gene expression and protein 
secretion = increase
TGF-2 gene expression and protein 
secretion = decrease
 
Apoptosis and necrosis after 
48hours = decrease
Inhibition of 
apoptosis and 
necrosis
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MMP assay & Sytox Green  assay 
Ex vivo HF containing skin 
specimens (2 male donors, occipital 
scalp)
Treated with 0.1% caffeine in 
PEG6000 solution vehicle for 6 days 
(cons) and subjected to combined 
UVB and UVA radiation on day 3. 
Hematoxylin staining
Melanin staining (Fontana-Masson)
Ki-67 immunostaining 
TUNEL immunostaining 
Percentage-fold change in sunburn 
cells (epidermal) caffeine treated vs. 
vehicle treated = reduced 
Melanin clumping in the HF in 
presence of caffeine in comparison 
with control vehicle = reduced  
ORS cells % change in distal (d), 
central (c) and proximal (p) position 
within the HF = differentiated effect 
of caffeine &UV at different locations 
IFG-1 and TGF-2 = increased for 
HF ORS (p) 
Percentage of Ki-67 cells and 
TUNEL HMK cells = reduced 
apoptosis
UV-induced 
damage reduction 
of the HF 
surrounding 
epidermis
UV protection in 
the HF epithelium
UV mediated 
damage i.e. 
apoptosis effect is 
more prominent 
in the distal HF, 
but is elevated by 
caffeine
[3]
In vivo, healthy volunteers, n=10. 
Dosed application of 1% caffeine 
shampoo (2mins contact time) 
Laser scanning microscopy of water-
soluble fluorescent dye as a proxy 
for caffeine after 2min, 24h and 48h 
= caffeine detected up to 48hours 
Water soluble 
actives can reach 
depth of 200 m, 
suggested access 
to the blood 
capillaries 
[4]
In vivo, healthy female volunteers, 
n=10.  Dosed shampoo application 
on defined area of the scalp (2mins 
contact time)
Laser scanning microscopy of water-
soluble fluorescent dye as a proxy 
for caffeine up to 24h after 
application= caffeine detected 
Average 
penetration depth 
= 185 m, access 
the blood 
capillaries
Lademann 
et al 
Laser 
Physics 
2010, Vol. 
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20, No. 2, pp. 
551–556
In vivo, healthy male volunteers, 
n=6. 2.5% caffeine solution applied 
to a defined area of the chest, HFs 
blocked with waxes vs open HF 
Blood serum analysis for caffeine up 
to 72 hours after application = 
caffeine detected
Follicular 
penetration route 
for caffeine 
[5]
 In vivo - open label (males with 
AGA, Hamilton-Norwood stages III-
V) n=210 
Leave-on solution application twice a 
day; 0.2% caffeine vs 5% minoxidil
Percentage change in anagen hairs 
measured using frontal and occipital 
trichograms = increase 
Stimulation of cell 
proliferation 
(HFK) and 5 α-
reductase 
inhibition
[6]
Ex vivo HF, organ culture from the 
occipital scalp of healthy males, n=3
Hair shaft elongation in 1µM ECGC 
= increased 
Prolongation of 
analgen phase 
In vitro, DPCs from occipital scalp 
follicles of healthy males, n=3 
MTT assay
Western blot analysis 
DPC proliferation = increased
Erk and Akt = increased 
Bcl-2 = increased, Bax = decreased Inhibition of 
apoptosis
[7]EGCG 
(Camellia 
sinensis)
In vitro/ex vivo 
studies 
In vitro, DHT-treated DPCs from a 
healthy male after 24h
WST-1
Cell cycle analysis
Cell viability, after exposure to 
EGCG+DHT= increased 
Cell cycle = extended
Cell senescence = reduced
Arresting the DHT 
Reduction of 
oxidative cell 
damage and 
[8]
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Cell senescence detection 
QR-PCR
Fluorescence-based oxidation-
sensitive probe
Altered miRNA profiles: predicting up 
and down regulation of IGF-1 and 
VEGF
Intra cellular ROS = reduced
related 
senescence 
 Gene expression  
In vitro and ex vivo using cell culture 
donors: AA patients n=30 vs healthy 
control n=30 
HaCat cells and Jurkat cells (in vitro) 
PBMC followed by FACS analysis
All cells were incubated in IFN-γ and 
treated with EGCG for variable time 
and concentrations
Western blot analysis in vitro and ex 
vivo cells
ELISA assay and Q-PCR 
pSTAT1 = reduced, IRF-1= reduced
Pro inflammatory T cells and gene 
expression = reduced 
IFN- signalling 
inhibition
Immunological 
action
[9]
EGCG
Camellia 
sinensis 
In vivo 
application/in 
vitro study
In vivo, aged skin n=5, 10% EGCG 
applied three times a week for 6 
weeks
In vitro, normal human epidermal 
keratinocytes, different doses 
applied 2-5 days
10%, 1h post treatment
Ki-67 immunostaining 
Epidermal thickness =increase
HMK cell proliferation = increase  
Cell proliferation/viability (MTT) = 
dose dependent increase 
Erk and Akt = increased 
Bcl-2 increase, Bax = decreased
Induced cell 
proliferation and 
survival 
[10]
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MTT assay
ELISA assay
Procyanadin B-
2 Malus pumila 
In vitro and ex 
vivo studies
In vivo, male with pattern balding 
according to Ogata scale, n=29, 
double blind, placebo controlled, 1% 
tonic application for 6 months 
Phototrichograms used to measure:
Total hair count = increased
Ratio of terminal/all hair based on 
diameter measurements of clipped 
hair = increased  
Suppression of 
inflammation 
[11]
Polyphenols 
(phlorofurofucoe
ckol A, eckol, 
dieckol)
Ecklonia cava
In vitro and ex 
vivo studies
In vitro and ex vivo, 12 healthy male 
donors for HFs and DPCs (occipital 
area)   
MTT assay,  minoxidil positive 
control 
Q-PCR analysis, polyphenols vs 
dimethyl sulfoxide
DPC and H2O2 treatment for ROS 
(oxidation sensitive and 
fluorescence-based measurements)
HF organ culture in various 
concentrations of active component 
vs  dimethyl sulfoxide 
Cell proliferation - increased 
mRNA expression of IGF-1 and 
VEGF = increased
Oxidative stress =  reduced 
Increased hair shaft production over 
9 days
Growth promotion 
and ROS 
scavenging 
[12]
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Proprietary 
herbal blend:    
Chamaemelum 
nobile,  Althaea 
officinalis, 
Persea 
Americana, 
Rosmarinus 
Aloe officinalis 
vera, Urtica 
dioica , Thymus 
vulgaris 
In vivo study
In vitro, DPCs obtained from HF 
organ culture from the occipital scalp 
of healthy males n=5
qRT-PCR assay of 5-R1 and 5-
R2 expression after treatment with 
different concentrations of herbal 
extract
MTT and B assays DPC treated with 
different concentrations of the herbal 
extract in the presence and absence 
of Akt1/2 for 48h
Cell proliferation (BrdU)
DPC treated with different 
concentrations of the herbal extract
Expression of 5 R2 in DPC = 
decrease
DPC viability = increase 
G1 phase progression proteins = 
increase
GAPDH, p-ERK and p-Akt = 
increase
Bcl-2 =increase 
Bax = decrease
5α-reductase 2 
inhibition
Inhibition of 
apoptosis
Cell cycle 
regulation
[13]
In vitro: normal human dermal 
fibroblasts stimulated with IL-1 in 
presence of active variables vs 
positive and negative control
IL-8 secretion = reduced Reduced micro-
inflammation 
Trifolium 
pratense flower 
extract 
(including 
isoflavone + 
biochanin;  
biometric 
peptide  added 
in some tests)
In vitro and in 
vivo studies 
In vivo, healthy volunteers with mild 
to moderate hair loss undefined 
rating, n=30, placebo controlled 5% 
active solution, daily application over 
4 months
Trichoscan recording 
anagen/telogen ratio = increased
Combined effects 
of 5 α-reductase 
inhibition, 
reduced 
microinflammatio
n and stimulation 
of extracellular 
matrix  
[14]
Page 32 of 42
International Journal of Cosmetic Science
International Journal of Cosmetic Science
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Rosebery 
ketone
Rubus idaeus
In vivo study
In vivo, male and female patients 
(mixed group AA and AGA), daily 
application of 0.01% solution vs. 
vehicle for 5 months 
Clinician’s grading baseline vs. 5 
months 
Hair growth rates in 50% of active 
treated group = increased
Stimulation of 
IGF-1, thus HKC 
proliferation
Increased dermal 
blood flow 
Down regulation 
of androgen 
receptors in the 
DPC
[15]
Capsaicin 
Capsicum 
annuum L
In vivo study
In vivo, AA patchy patients (<30% 
scalp involvement) n=50 capsaicin 
vs clobestol (positive control), 
application for 4 weeks,   
Clinician’s assessment after 12 
weeks (grading scale)
Hair grading in both groups = 
statistically not different
Stimulates the 
perifollicular 
nerves and the 
HF immune 
system
[16]
Rosemary oil 
Rosmarinus 
officinalis L
In vivo study
In vivo AGA patients (n=50), topical 
application, positive control = 2% 
minoxidil  
 
Clinician’s assessment after 6 
months (grading scale)
Self-assessment 
Hair grading in both groups = 
statistically not different
Rosemary group = self-reported 
reduced scalp itches and irritation 
 
[17]
Crude onion 
juice
Allium cepa L 
 
In vivo study
In vivo, AA patients, n=46 crude 
juice vs placebo (water) applied to 
affected area 2 times per day   
Clinician’s assessment in intervals 
up to 2 months (grading scale)
Hair growth of terminal hair = 
declared after 2 weeks in active 
treatment group and increased as a 
percentage of observations within 
the group, vs statistically lower % of 
observations in the placebo group
Induction of 
immunological 
reaction and 
antigenic 
competition 
[18]
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Saw palmetto 
(Serenoa 
repens)
In vivo study
AGA male patients (Norwood-
Hamilton types III, IV, V, VI), n=50, 
within subject comparison of active 
lotion after 12 weeks 
Phototrichogram 
Clinician assessment 
Self-assessment (validated scales) 
Terminal hair count = increased 
Vellus hair count = decrease 
Results 12-24 weeks = inconsistent 
5 α-reductase 
inhibition by the 
fatty acid present 
in the SP
[19]
Proprietary 
herbal blend 
Urtica uren, 
Urtica dioica, 
Matricaria 
chamomilla, 
Achillea 
millefolium, 
Ceratonia sili- 
qua, Equisetum 
arvense  
In vivo study
Males AGA grade II-III Hamilton 
Norwood, and n-66 female with 
Telogen Effluvium, n=54 assigned to 
four treatment groups, 
active shampoo, active leave on 
solution, a combination of the above, 
placebo,
Blind clinician’s assessment – pull 
test, phototrichogram up to 6 months 
Self-assessment 
Total hair count, Telogen/Anagen 
ratio after 2,4- and 6-months 
treatment: increase for each time 
point in comparison to T0. 
Self-evaluation (questionnaire) 
scores – higher score for all active 
treatments vs. placebo 
Synergistic 
combined effect 
on HF
[20] 
Red ginseng 
extract 
Panax ginseng
DPC cells obtained from non-balding 
scalp (hair transplantation surgery) 
DPCs + various concentration of G-
Rb1 incubated (2h) with CCK-8 
Cell proliferation: increase in a dose 
-dependent manner 
p-Erk and pAkt expression: increase 
Increased cell 
proliferation 
Reduce DHT 
[21]
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(RGE)+ 
ginsenoside 
Rb1 and 
ginsenoside 
Rg3
In vitro study 
ELISA of various concentration of 
RGE and G Rb-1 incubated with 
primary antibodies 
KI-67 assay: DHT pre-treated DPC, 
incubated with RGE, G-Rb1 and G-
Rg3 at different concentration
RT-PCR of the androgen receptor 
expression 
Ki-67cell positivity = increase in 
presence of actives
Actives reduced expression 
Induced up-
regulation of 
androgen 
receptor 
Ginsenoside 
F1 (mixed 
sources) 
Panax ginseng
In vitro, UVB-radiated normal human 
epidermal keratinocytes, different 
active doses applied for 24h 
MTT assay
TUNEL assay
ELISA
Cell proliferation/viability = dose 
dependent increase for up to 
90mJ/cm
DNA fragmentation = reduced
Bcl-2 increased, Bax = decreased
Protection against 
UV-B induced 
apoptosis 
[22]
Oral treatments
Capsaicin and 
isoflavone 
(origin not 
disclosed) 
 In vivo study
In vivo patients AGA, AA, AT (n=47),  
placebo controlled, double blind trial 
for 5 months
Blind clinician’s assessment 
IGF-1 serum levels 
IFG-1 level in serum 
Hair growth assessment based in 
photographs for patients 5 months 
vs. base line in active treatment = 
increased
IGF-1 serum levels for patients after 
5 months vs base line in active 
treatment = increased 
Increase in IGF-1 
suppresses TGF-
β-induced 
apoptosis 
[23]
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Saw palmetto + 
-sitosterol 
Serenoa repens
In vivo study
In vivo AGA patients (Norwood -
Hamilton types II-VI vertex), n=49 
daily supplements for 21 weeks, 
double blind, placebo controlled 
Blind clinician’s assessment 
Self-assessment 
Improvement ratings = increased 
Self-reported improvement of bold 
patches=in active group only 
5 α-reductase 
inhibition 
[24]
Saw palmetto 
Serenoa repens
In vivo study
In vivo, male AGA patients (Hamilton 
classification I to IV) n=100,  
24 monthly daily oral treatment 
active vs. finasteride (open trial) 
Global photos, used for baldness 
score (Hamilton) start and end of 
treatment
Hair growth in the vertex induced by 
active finasteride (vertex and 
occipital area)
5 α-reductase 
inhibition by the 
fatty acid present 
in the SP
[25]
Pumpkin seed 
oil 
Cucurbita pepo 
In vivo study
In vivo, AGA male patients 
(Norwood-Hamilton types II, III, III 
Vertex, IV and V), n=76
Placebo controlled, blind trial, 24 
weeks 
Phototrichograms 
Clinician’s grading 
Self-assessment
Hair count=incr ase; hair 
thickness=increase
Mean score of clinical grades = 
increase 
5 α-reductase 
inhibition
[26]
Proprietary 
blend 
Vitamin C 
(acerola powder 
and ascorbic 
AGA males with pattern hair 
(Norwood-Hamilton scale II,II, III), 
n=60
Placebo controlled for 180 days 
Total hair count, total hair density, 
terminal hair density = increased 
Hair removal = reduced
Improved wellbeing scores 
Systemic effect [27]
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acid), zinc (from 
zinc oxide), 
shark powder 
and mollusk 
powder, 
horsetail (stem) 
extract and flax 
seed extract  
Phototrichogram 
Hair pull test 
Quality of life questionnaire 
Proprietary 
blend 
Including; 
horsetail derived 
silica, Vit C from 
acerola chilly 
and procyanidin 
B-2marine 
complex 
Healthy females (n=40), placebo 
control taking the oral supplement 
for 180 days
Phototrichogram 
Self-assessment 
 
Terminal hair density  = increased 
Hair diameter: increased 
Increased hair diameter 
Self-reported hair volume, texture, 
as well as nails and skin related 
parameters
Self-reported hair volume, texture, 
as well as nails and skin related 
parameters 
Systemic effect [28]
Proprietary 
blend including 
horsetail 
derived silica, 
vit C from 
acerola chilli 
and 
procyanidin B-
2 marine 
complex 
Healthy females (n=72), placebo 
controlled, taking the oral 
supplement for 180 days
Phototrichogram 
Self-assessment 
Hair shedding = reduced
Vellus-like hair diameter = increased 
Increased hair diameter 
Self-reported hair volume, texture, 
as well as nails and skin related 
parameters
Systemic effect [29]
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Table III. Legend of abbreviations and terms used in Table II. 
AGA Androgenic alopecia
AA Alopecia areata
Akt and pAkt Protein kinase/phosphorylated Akt, a protein promoting cell survival
Bcl-2/Bax B-cell lymphoma 2, protein regulator inhibiting apoptosis    
Bcl-2 like protein 4, protein regulating inducing apoptosis      
CyQUANT Fluorescence-based assay measuring cell proliferation, based on cellular DNA content
DPC Dermal papilla cells 
DHT Dehydrotestosterone, an androgen responsible for follicle miniaturisation 
EGCG Epigallocatechin 3-gallate, the most abundant catechin in tea
ELISA Enzyme-linked immunological assay used to detect and quantify the presence of proteins, enzymes and antibodies 
 
Erk Extracellular signal-regulated kinases promoting cell survival 
FACS Fluorescence-activated cell sorting of biological cell mixtures 
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GAPDH Glyceraldehyde 3-phosphate dehydrogenase, an enzyme catalysing a step in the glucose break down
HFK Hair follicle keratinocytes 
IFG-1 Insulin-like growth factor-1, a growth mediator 
IL-8 Interleukin 8, a proinflammatory cytokine 
KGF Keratinocyte growth factor involved in skin healing 
Ki-67  Immunostaining assay (colorimetric) detecting Ki-67 protein expression, associated with cell proliferation, thus 
providing a marker for the proportion of proliferating cells
MMP Mitochondrial Membrane Potential Assay measuring the onset of apoptosis
MTT A colorimetric assay used to measure cell viability/proliferation 
ORS Outer Root Sheath
PBMC Peripheral blood mononuclear cell used to predict immunosuppressive effects
STAT1/pSTAT1 Signal transducer and activator of transcription (phosphorylated) plays a major role  in immune responses
Sytox Cell viability assay based on fluorescence, also used for cell apoptosis  
TUNEL Terminal Deoxynucleotidyl transferase dUTP nick end labelling, immunostaining assay detecting DNA 
fragmentation in cells, providing a marker for apoptotic cells 
TGF-2 Transforming growth factor 2, a protein suppressing cell proliferation and associated with the hair follicle’s entry in 
catagen   
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Q-PCR or qRT-
PCR
Quantitative (Q) or reverse transcription polymerase chain reaction, measuring the DNA or mitochondrial RNA, 
used as a marker for expressing growth factors and cycle transition 
Western blot 
analysis
Gel electrophoresis, used to separate a mixture of proteins, concentrations measured via spectrophotometer
WST-1 Colorimetric assay quantifying viable cells/cell proliferation 
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